Terms: = Liver cancer AND TERT, EST2, Q8NG46, Q8N6C3, Q2XS35, O14783, O14746, 7015, hEST2, TCS1, TRT, TP2 AND Treatment
141 results:
1. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
2. Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.
Li HY; Zheng LL; Hu N; Wang ZH; Tao CC; Wang YR; Liu Y; Aizimuaji Z; Wang HW; Zheng RQ; Xiao T; Rong WQ
World J Gastroenterol; 2024 Mar; 30(9):1224-1236. PubMed ID: 38577190
[TBL] [Abstract] [Full Text] [Related]
3. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
4. Investigating the molecular mechanism of Qizhu anticancer prescription in inhibiting hepatocellular carcinoma based on high-resolution mass spectrometry and network pharmacology.
Sun J; Ma M; Zhong X; Li J; Yi J; Zhang R; Liu X; Peng L; Sun X; Feng W; Hu R; Huang Q; Lv M; Fan K; Zhou X
J Ethnopharmacol; 2024 Jun; 328():117985. PubMed ID: 38417600
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and predictive biomarkers in paediatric solid tumours.
Glembocki AI; Somers GR
Pathology; 2024 Mar; 56(2):283-296. PubMed ID: 38216399
[TBL] [Abstract] [Full Text] [Related]
6. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma.
Zhou S; Sarabia SF; Estrine D; Ostrow D; Schmidt RJ; Warren M; Raca G; Shillingford N; Wang L; Pawel B; Stein JE; Biegel JA; Lopez-Terrada D; Mascarenhas L; Ji J
Mod Pathol; 2024 Feb; 37(2):100385. PubMed ID: 37992967
[TBL] [Abstract] [Full Text] [Related]
7. Intrathoracic Progression Is Still the Most Dominant Failure Pattern after First-Line Chemo-immunotherapy in Extensive-Stage Small-Cell Lung cancer: Implications for Thoracic Radiotherapy.
Kim D; Kim HJ; Wu HG; Lee JH; Kim S; Kim TM; Kim JS; Kim BH
Cancer Res Treat; 2024 Apr; 56(2):430-441. PubMed ID: 37933113
[TBL] [Abstract] [Full Text] [Related]
8. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.
Fang M; Wang L; Gu Q; Wu H; Du X; Lai X
Clin Exp Metastasis; 2023 Oct; 40(5):423-429. PubMed ID: 37584783
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (tertIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract] [Full Text] [Related]
11. Calix[4]arene-pyrazole conjugates as potential cancer therapeutics.
Muravev AA; Voloshina AD; Sapunova AS; Gabdrakhmanova FB; Lenina OA; Petrov KA; Shityakov S; Skorb EV; Solovieva SE; Antipin IS
Bioorg Chem; 2023 Oct; 139():106742. PubMed ID: 37480816
[TBL] [Abstract] [Full Text] [Related]
12. The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma.
Innes H; Morgan MY; Hampe J; Stickel F; Buch S
Aliment Pharmacol Ther; 2023 Sep; 58(6):623-631. PubMed ID: 37470344
[TBL] [Abstract] [Full Text] [Related]
13. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
Peng J; Zhang L; Wang L; Feng H; Yao D; Meng R; Liu X; Li X; Liu N; Tan B; Huang Z; Li S; Meng X
Radiat Oncol; 2023 Jul; 18(1):111. PubMed ID: 37403111
[TBL] [Abstract] [Full Text] [Related]
14. Genomic profile of Pancoast syndrome due to hepatocellular carcinoma: A case report.
Bergman DT; Zaki L; Pettus JR; Zaki BI; Amin M
Thorac Cancer; 2023 Jun; 14(18):1789-1792. PubMed ID: 37160416
[TBL] [Abstract] [Full Text] [Related]
15. [Differential diagnostic between hepatocellular carcinoma and hepatoid carcinoma with bone metastasis revelation: What tools can be used?].
Neyrand S; Bringuier PP; Benzerdjeb N; Hervieu V; Fenouil T
Ann Pathol; 2023 Sep; 43(5):407-411. PubMed ID: 36822899
[TBL] [Abstract] [Full Text] [Related]
16. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
Yoshuantari N; Jeng YM; Liau JY; Lee CH; Tsai JH
Mod Pathol; 2023 Jan; 36(1):100042. PubMed ID: 36788061
[TBL] [Abstract] [Full Text] [Related]
17. [The expression and function of PD-L1 in CD133(+) human liver cancer stem-like cells].
Bai YD; Shi ML; Li SQ; Wang XL; Peng JJ; Zhou DJ; Sun FF; Li H; Wang C; Du M; Zhang T; Li D
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):117-128. PubMed ID: 36781232
[No Abstract] [Full Text] [Related]
18. Synthesis and biological evaluation of tert-butyl ester and ethyl ester prodrugs of L-γ-methyleneglutamic acid amides for cancer.
Khan MIH; Mahdi F; Penfornis P; Akins NS; Hossain MI; Kim SJ; Sulochana SP; Adam AT; Tran TD; Tan C; Paolo Claudio P; Paris JJ; Le HV
Bioorg Med Chem; 2023 Jan; 78():117137. PubMed ID: 36603398
[TBL] [Abstract] [Full Text] [Related]
19. Profound tumor response to combined CTLA-4 and PD-1 inhibition in systemic fourth line therapy observed in a patient with hepatocellular carcinoma harboring SETD2 and LRP1B mutations.
Reiter FP; Rau M; Kunzmann V; Kickuth R; Klein I; Neumann O; Stenzinger A; Schirmacher P; Geier A
Z Gastroenterol; 2023 Jan; 61(1):71-75. PubMed ID: 36379463
[TBL] [Abstract] [Full Text] [Related]
20. Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data.
Tornesello ML; Tornesello AL; Starita N; Cerasuolo A; Izzo F; Buonaguro L; Buonaguro FM
Expert Opin Ther Targets; 2022 Sep; 26(9):767-780. PubMed ID: 36369706
[TBL] [Abstract] [Full Text] [Related]
[Next]
